Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark BlueShield NENY Ajovy Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Medication Prior Authorization Form — Ajovy (fremanezumab) for Migraine Prevention

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and requirements for prior authorization of Ajovy (fremanezumab) for migraine prophylaxis, used by providers submitting requests for Highmark BlueShield members in North Carolina.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication Prior Authorization Form — Ajovy (fremanezumab) for Migraine Prevention
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical information and supporting documentation; fax to 1-866-240-8123.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1medication per form
    50%reauthorization reduction
    4 daysepisodic response

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1-866-240-8123fax to submit

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis: Provider selects episodic or chronic migraine diagnosis (or lists other diagnosis with ICD-10).

    Episodic: 4-14 headache days/month; Chronic: ≥15 headache days/month, of which ≥8 are migraine days.

    Baseline frequency: Provide average number of migraine days per month prior to starting Ajovy.

    Used to determine episodic vs chronic per diagnosis selection on form.

    Medication overuse assessment: Confirm whether headaches are caused by medication rebound/overutilization (e.g., narcotics or triptans >18 doses/month) or lifestyle factors.

    If overuse present, documentation is required and may affect eligibility.

    Prior preventive therapy: Document therapeutic failure or intolerance to one or more relevant preventive medication classes.

    Includes anti-epileptic drugs, beta-blockers, calcium-channel blockers, SNRIs, tricyclic antidepressants, Botox, alpha-agonists, ACE inhibitors/ARBs, or other listed agents.

    Continuation / Reauthorization

    Covered for continuation when the following response is documented:

    Clinical response for chronic migraine: Member has experienced at least a 50% reduction in number of migraine days per month compared to start of therapy.>=50% reduction

    Form requests Yes/No response for reauthorization.

    Clinical response for episodic migraine: For episodic migraine, member has experienced a reduction of at least 4 monthly migraine days since the start of therapy.>=4 day reduction

    Form requests Yes/No response for reauthorization.

    Concurrent Therapy

    Concurrent use rules:

    Concurrent CGRP use: Provider must indicate whether Ajovy will be used in combination with another CGRP inhibitor for acute use.

    If yes, provider must state that the benefits of concurrent use outweigh the risks and provide justification (Yes/No and benefit-risk justification required on form).

    Assess and document whether the member's headaches are attributable to medication overuse or modifiable lifestyle factors. The form asks specifically if headaches are due to medication rebound/overutilization (defined on the form as taking narcotics or triptans in excess of 18 doses per month) or lifestyle contributors (for example, sleep patterns or caffeine use). If medication overuse is present, this must be identified and addressed in the clinical record because overuse is an alternate cause of headache and may preclude coverage of migraine prophylaxis until appropriately managed.

    Authorization of Ajovy requires submission of a completed prior authorization form, but authorization does not guarantee payment. Payment is subject to the member's eligibility and plan benefits at the time of claim adjudication; ensure the member is eligible and that the requested service is covered under the member's policy.

    Coding

    Diagnosis codes (general)ICD-10
    Otherfield for diagnosis and/or ICD-10 code
    Drug identificationNDC
    NDCDrug name/strength/quantity fields (medication-specific)
    Response thresholds for continuation
    General continuation response>= 50% reduction in monthly migraine days compared to start of therapy
    Episodic migraine response>= 4-day reduction in monthly migraine days since start of therapy
    DocumentationForm includes Yes/No fields to indicate whether response criteria are met for reauthorization

    Provider Actions & Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required — submit one completed Medication Prior Authorization Form per medication. Fax to 1-866-240-8123 or mail per form instructions. The prescribing physician (PCP or specialist) should, in most cases, complete and sign the form.

    • Submit one form per medication
    • Fax: 1-866-240-8123
    Documentation Required

    Document Prior Preventive Therapy Failures

    Document prior preventive therapy failures or intolerances. The form must indicate therapeutic failure or intolerance to specified preventive migraine medication classes (e.g., anti-epileptic drugs, beta-blockers, calcium-channel blockers, SNRIs, tricyclic antidepressants, Botox, alpha-agonists, ACE inhibitors/ARBs) or list other relevant agents.

    • Anti-epileptic drugs (e.g., topiramate, valproic acid)

    Initial Authorization Criteria

    Initial Authorization

    Initial Authorization

    Required documentation: Diagnosis (episodic or chronic migraine or other with ICD-10), baseline average monthly migraine days, and assessment for medication overuse/lifestyle factors must be provided.

    Form includes fields for diagnosis selection, baseline days per month, and overuse assessment.

    Prior preventive therapy failures/intolerances: Document therapeutic failure or intolerance to applicable preventive medication classes before initiating Ajovy.

    Includes anti-epileptics, beta-blockers, calcium-channel blockers, SNRIs, tricyclics, Botox, alpha-agonists, ACE inhibitors/ARBs, or other agents listed on the form.

    Form completion requirements: Submit a separate, fully completed form for this medication with physician address and required provider signature; fax or mail as instructed.

    Incomplete forms or missing physician address may lead to denial or delay; fax to 1-866-240-8123.

    Reauthorization / Continuation Criteria

    Reauthorization

    Reauthorization

    Documented clinical improvement: Provider must document clinical improvement since therapy start: either ≥50% reduction in monthly migraine days (chronic) or ≥4-day reduction (episodic).see criteria

    Form includes Yes/No fields for these response thresholds; authorization for continuation is contingent on meeting the applicable threshold.

    Step Therapy

    StepRequirement
    1Provider must document therapeutic failure or intolerance to one or more of the following preventive medication classes: anti-epileptic drugs (e.g., topiramate, valproic acid, divalproex sodium, carbamazepine), beta-blockers (e.g., propranolol, timolol, metoprolol), calcium-channel blockers (e.g., verapamil, amlodipine), serotonin–norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine), tricyclic antidepressants (e.g., amitriptyline, nortriptyline), Botox, alpha-agonists (e.g., clonidine, guanfacine), ACE inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan), or other listed agents.

    Quantity Limits

    Ajovy — Quantity / Supply
    Requested quantityRequested Quantity must be specified on the form
    Requested supply day options30 days, 90 days, or Other (specify)
    DirectionsDirections for use must be provided alongside quantity/supply information

    Site of Care

    Note

    Site-of-care note — medication strength, directions, and supply requested

    The form requests medication strength, directions, and the requested supply (30 days, 90 days, or other); no specific site-of-care restriction is stated on the form.

    • Medication fields: drug name, drug strength, requested quantity, requested supply day (30 days, 90 days, other), directions.

    Definitions

    Episodic migraine — definition
    Episodic migraine definition4-14 headache days per month
    Diagnostic selectionForm asks provider to select Episodic Migraine Prophylaxis when 4-14 headache days/month
    Use in coverage determinationBaseline average monthly headache days is collected to determine episodic vs chronic categorization
    Chronic migraine — definition
    Chronic migraine definition15 or more headache days per month, of which 8 or more are migraine days
    Diagnostic selectionForm asks provider to select Chronic Migraine Prophylaxis when criteria of 15+ headache days/month with >=8 migraine days are met

    Background

    Ajovy (fremanezumab) is a monoclonal antibody indicated for migraine prophylaxis in both episodic migraine (4–14 headache days per month) and chronic migraine (≥15 headache days per month, of which ≥8 are migraine days). The prior authorization form is used to collect baseline migraine frequency, confirm the appropriate diagnosis, assess for medication overuse or lifestyle contributors to headache, document prior preventive therapy failures or intolerances, and capture response data for reauthorization. For initial requests the form asks for the average number of migraine days per month prior to starting Ajovy; for reauthorization the form documents clinical response, including a required ≥50% reduction in monthly migraine days for chronic migraine or a ≥4-day reduction in monthly migraine days for episodic migraine.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication Prior Authorization Form — Ajovy (fremanezumab) for Migraine Prevention
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical information and supporting documentation; fax to 1-866-240-8123.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & Submission RequirementsInitial Authorization CriteriaReauthorization / Continuation CriteriaStep TherapyQuantity LimitsSite of CareDefinitionsBackground
  1. Beta-blockers (e.g., propranolol, metoprolol)
  2. Calcium-channel blockers (e.g., verapamil, amlodipine)
  3. SNRIs (e.g., venlafaxine, duloxetine)
  4. Tricyclic antidepressants (e.g., amitriptyline)
  5. Botox
  6. Alpha-agonists (e.g., clonidine)
  7. ACE inhibitors/ARBs (e.g., lisinopril, candesartan)
  8. Other — specify
  9. Note

    Submission Requirements — Completed Form & Supporting Documentation

    Submit the completed form with all required member and provider information, medication details, and supporting clinical documentation. Include: member name, subscriber ID and group number, DOB, contact info; physician name, NPI, phone, fax, full address, and physician signature/date; drug name, strength, quantity, days' supply, directions; and completed clinical fields (diagnosis, baseline migraine days, medication history, rationale for therapy, and reauthorization response if applicable).

    • Member information: name, subscriber ID, group number, DOB, phone, address
    • Provider information: physician name, NPI, phone, fax, full address, signature, date
    • Medication information: drug name, strength, quantity, days' supply, directions
    • Clinical information: diagnosis, average migraine days/month, cause of headaches, prior therapy failures/intolerances, concurrent CGRP use, reauthorization response
    Denial Risk

    Incomplete Form Risk — Provide All Required Information

    Incomplete forms or missing required information may result in denial or delay. Be sure to complete all fields, provide the physician address (required for physician notification), and include all supporting clinical documentation. Failure to complete all information or provide the required physician address may lead to denial or delay.

    • Failure to complete all requested information may delay or deny the request
    • Physician address is required for notification
    • Include supporting clinical documentation to avoid processing delays
    Baseline assessment
    Average number of migraine days per month prior to starting Ajovy is collected to confirm chronic migraine